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The Darkening Cloud of Diabetes
Do trends in cardiovascular risk management provide a silver lining?
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OBJECTIVE — We aimed to evaluate the changes in cardiovascular-related health care uti-
lization (drug therapies, hospitalizations) and mortality for the diabetic population during a
9-year period in Saskatchewan, Canada.
RESEARCH DESIGN AND METHODS — We identiﬁed annual diabetes prevalence
rates for people aged 30 years between 1993 and 2001 from the administrative databases of
Saskatchewan Health. Annual rates of evidence-based drug therapies (antihypertensives, ACE
inhibitors,-blockers,calciumchannelblockers,3-hydroxy-3-metaglutarylcoenzymeAreduc-
tase inhibitors [statins]), hospitalizations for cerebrovascular and cardiac events, and all-cause
mortality were estimated. Rates were direct age and sex standardized using the 2001 Canadian
population, and trends over time were assessed using Joinpoint regression.
RESULTS — From 1993 to 2001, diabetes prevalence increased 34% (4.7–6.5%, P  0.001)
with the highest rates in men and those aged 65 years. The rate of increase in diabetes
prevalence appeared to slow in those aged 65 years (P  0.01 for trend). Signiﬁcant increased
use of evidence-based drug therapies was observed (41% increase in antihypertensive agents,
97%increaseinACEinhibitors,223%increaseinstatintherapies;allP0.05fortrend).During
this period, both cerebrovascular and cardiac-related hospitalizations declined by 36% (9.5 vs.
6.1per1,000)and19%(38.0vs.30.6per1,000)(P0.05fortrends),respectively,withsimilar
reductionsregardlessofsex.Nochangeinall-causemortalitywasobserved(17.7vs.17.8deaths
per 1,000; P  0.05).
CONCLUSIONS — During our period of study, there was an increase in the utilization of
evidenced-baseddrugtherapiesinpeoplewithdiabetesandreductionsincardiovascular-related
hospitalizations. Despite this, we observed no change in all-cause mortality.
Diabetes Care 31:2136–2142, 2008
D
iabetes represents a major public
healthburden,bothlocallyandglo-
bally (1). From 1985 to 2000, the
number of people living with diabetes
globally rose from 30 million to 171
million (1). Future projections have esti-
mated the prevalence of diabetes to ex-
ceed 300 million cases by 2030, with the
majority of growth occurring in develop-
ing countries (1). Recent estimates, how-
ever, suggest that these projections may
grosslyunderestimatethetrueprevalence
(2).
It is well known that diabetes is asso-
ciated with signiﬁcant morbidity and
mortality. It is estimated that there are six
deaths every minute attributable to the
complications of diabetes, with cardio-
vascular disease being responsible for the
vast majority (3). Not surprisingly, diabe-
tes and its complications place an enor-
mous burden on both patients and the
healthcaresystem,withdirecthealthcare
costs ranging from 2.5 to 15% of annual
health care budgets (4). Given the ex-
pected rise in diabetes cases, this eco-
nomic burden will also increase.
For these reasons, considerable re-
sources have been invested to improve
diabetes management. In addition to life-
style changes, a cornerstone of this man-
agement scheme has been the use of
evidence-based drug therapies for vascu-
lar protection (5). Large trials have dem-
onstrated that aggressive pharmacologic
management of cardiovascular risks can
reduce both morbidity and mortality in
patients with diabetes (5). It would also
appear that the diabetic community is in-
corporating this evidence into the daily
management of diabetic patients. Several
studies (6–9) have reported signiﬁcant
increases in the use of evidence-based
drug therapies in people with diabetes.
However, previous studies have largely
focused on antihyperglycemic manage-
ment (7,8) or have been restricted to spe-
ciﬁc subpopulations of patients with
diabetes (e.g., aged 65 years) (6,9).
The increased prevalence of diabetes
hasbeenattributednotonlytoanincrease
inincidencebutalsotoreducedmortality
rates (2,10). A decrease in mortality rates
over time in people with diabetes has
been reported in both Canada and the
U.S. (2,10–14). It remains uncertain,
however, whether concurrent changes in
utilization rates of evidence-based drug
therapies over time has resulted in sub-
stantial improvements in the health of
people with diabetes at the population
level.Weareunawareofstudiesthathave
simultaneously evaluated the trends in
health care utilization and subsequent
changes in mortality in people with dia-
betes. Therefore, our objective was to ex-
plore both health care utilization patterns
(i.e., evidence-based drug therapies and
hospitalizations) and mortality rates over
a 9-year period in an unselected popula-
tion of patients with diabetes.
RESEARCH DESIGN AND
METHODS— Data were compiled
from the provincial administrative data-
bases for Saskatchewan Health. These da-
tabases have been extensively described
elsewhere and are considered to be both
high quality and comprehensive (15).
Saskatchewan Health provides universal
health coverage to 99% of the 1 million
people in Saskatchewan, Canada (15).
These databases include a demographic
and vital statistics population registry,
outpatient prescription drugs, hospital
separation data, and physician services
and are linkable through unique patient
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linked administrative datasets in most ju-
risdictions,theSaskatchewanHealthdata
include prescription drug information for
all ages (i.e., it is not restricted to the age
65 years subgroup). For these analyses,
registered Indians were excluded, as their
prescription drug beneﬁts are provided
by the federal government and are not in-
cluded in these datasets. Ethical approval
was obtained from the health ethics re-
search board of the University of Alberta.
Outcome assessment
Beneﬁciaries eligible for provincial pre-
scription drug beneﬁts, aged 30 years
with diabetes, were identiﬁed using the
previously validated Canadian National
Diabetes Surveillance System criteria
(16). Any individual having two physi-
cian visits on 2 different days within a
2-year period or one hospitalization with
a diagnosis of diabetes (ICD-9 code 250)
were identiﬁed as having diabetes (2,16).
Point prevalence on 31 December of each
year was used to determine annual diabe-
tes prevalence and all-cause mortality
rates.
Hospital separation records were
used to identify subjects with at least one
hospitalization for any reason (all cause)
orforcardiovascularreasonspercalendar
year. A hospitalization was categorized as
cardiovascular-related if the primary or
mostresponsiblediagnosiswascodedasa
cardiac disorder (ICD-9 codes 410–414
and425–429)oracerebrovasculardisor-
der(ICD-9codes430–438).Prescription
drug use was deﬁned as one or more pre-
scription claims for a medication within a
class during the calendar year. Evidence-
based drug therapies of interest included
the use of any antihypertensive medica-
tions (e.g., diuretics, -blockers, ACE in-
hibitors, angiotensin receptor II blockers,
calcium channel blockers [CCBs], or
-blockers; the use of ACE inhibitors,
-blockers,orCCBs,speciﬁcally;and,the
use of 3-hydroxy-3-metaglutaryl co-
enzyme A reductase inhibitors [statins]).
Statistical analyses
Allratesweredirectageandsexstandard-
izedusingthe2001Canadiancensusdata
to facilitate comparisons over time (2).
For yearly diabetes prevalence, all sub-
jects diagnosed with diabetes and alive at
any point in the year were included in the
numerator. The denominator was calcu-
lated as the total number of people aged
30 years in Saskatchewan who were el-
igible for beneﬁts within the province as
of 30 June of the calendar year. Similar
calculations were used for hospitaliza-
tions, prescription claims, and mortality,
with the numerator representing the total
number of people with diabetes who had
the event of interest (hospitalization, pre-
scription claim, or death) within the year
and the denominators representing all
subjects diagnosed with diabetes and
were alive at any point within the year.
Results are presented for both men and
women as well as for those aged 65 and
65 years.
Allageandsexstandardizedratesand
associatedSEswerecalculatedusingStata
Intercooled, version 10 (Stata, College
Station, TX). Trends in age- and sex-
standardized rates were calculated using
Joinpoint regression (http://srab.cancer.
gov/software/software.html).Thisformof
regression analysis has been used in nu-
merous evaluations of trend data and has
been previously described in detail (17).
Brieﬂy, this analysis begins by assuming
that there are no joinpoints (i.e., a simple
linear line) and, through a series of per-
mutations, tests whether the addition of
joinpoints (up to two joinpoints were
considered) results in a statistically sig-
niﬁcant linear change in direction or
magnitude of the rates. Parameter esti-
mates for each trend include the annual
percentage of change (APC) in rates and
associated 95% CI according to gener-
alized linear models that assumed a
Poisson distribution.
RESULTS— Between 1993 and 2001,
crude diabetes prevalence steadily in-
creasedby44%(from5.0to7.2%)(Table
1). After age and sex standardization, the
adjusted rates increased 34%(from4.7 to
6.5%), with an APC increase of 4.3%
(95% CI 3.8–4.8) (P  0.001) (Table 1
and Table 2). The difference in crude and
adjustedratessuggeststhatpartoftheob-
servedincreaseindiabetesisrelatedtothe
increasing age of the population.
Although men had a higher preva-
lence of diabetes compared with women
in 1993 (standardized rate ratio [sRR]
1.23 [95% CI 1.20–1.26]) and in 2001
(1.21[1.19–1.24]),theAPCincreasewas
similarbetweensexes(Table2).Similarly,
peopleaged65yearshadamuchhigher
prevalence of diabetes compared with
those aged 65 years in 1993 (sRR 3.84
[3.76–3.94]) and in 2001 (sRR 3.67
[3.59–3.74]), although the APC increase
was similar between age-groups (Table
2). Interestingly, in people aged 65
years, the increase in diabetes rates
slowed signiﬁcantly after 1998; 5.4%
APC before 1998 and 3.6% APC after
1998 (Table 2) (P  0.001 for rate
change).
Drug utilization
Between 1993 and 2001, the number of
people with at least one prescription
claim for an antihypertensive agent in-
creased signiﬁcantly from 345.8 to 487.1
per 1,000 people with diabetes, respec-
Table 1—Prevalence of diabetes in 1993 and 2001
All Men Women Aged 65 years Aged 65 years
1993
Covered population (n) 539,024 263,112 275,912 397,471 141,553
People with diabetes (n) 27,014 14,431 12,583 11,094 15,920
Crude rate (%) 5.0 5.5 4.6 2.8 11.2
Adjusted rate (%) 4.7* 5.2† 4.2† 2.9* 11.2*
2001
Covered population (n) 558,085 271,504 286,581 412,739 145,346
People with diabetes (n) 40,098 21,363 18,735 17,448 22,650
Crude rate (%) 7.2 7.9 6.5 4.2 15.6
Adjusted rate (%) 6.5* 7.2† 5.9† 4.2* 15.3*
*Age and sex adjusted to 2001 Canadian population; †age adjusted to 2001 Canadian population.
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utilization increased during this period,
utilization remained fairly constant be-
tween 1993 and 1996 (APC increase
1.5%, P  0.05 for trend), but thereafter
rates of antihypertensive use changed sig-
niﬁcantly with an APC increase of 6.3%
(P  0.001 for trend) (Table 2). The rate
of change differed, however, by sex and
age. Men had a substantially greater APC
increase in utilization compared with
women (6.3 vs. 3.7%), although overall
utilization rates remained signiﬁcantly
lower for men in 2001 (sRR 0.92 [95% CI
0.89–0.96]) (Table 2). Similarly, higher
utilization rates were observed in people
aged 65 years irrespective of time pe-
riod; however, those aged 65 years had
a substantially greater APC increase com-
pared with those aged 65 years (5.5 vs.
3.5%) (Table 2).
The use of ACE inhibitor therapy
nearly doubled between 1993 and 2001,
withanAPCincreaseof9.2%(P0.001)
(Table 2) (Fig. 1). The largest APC in-
crease in ACE inhibitor utilization was
observed in men, which was 35% greater
than the increase observed in women
(11.3 vs. 7.4%). Despite lower utilization
in 1993, men were more likely to use an
ACE inhibitor in 2001 compared with
women(34.8vs.31.2%,P0.05)(Table
2). The rates of ACE inhibitor utilization
also increased more signiﬁcantly in peo-
ple with diabetes aged 65 years com-
pared with those aged 65 years (APC
increase 9.9 vs. 7.6), with the highest uti-
lization increase occurring between 1997
and 2001 (Table 2).
-Blocker utilization initially de-
creased between 1993 and 1996 before
signiﬁcantly increasing in the remaining
years (Table 2) (Fig. 1). Men and women
showed a similar pattern of utilization.
People aged 65 years were much more
likely to use a -blocker compared with
thoseaged65years,irrespectiveoftime
period. In fact, the rate of increase of
-blockers was over twofold higher in
those aged 65 years compared with
those aged 65 years from 1993 to 2001
(APC 8.7 vs. 3.3%) (Table 2).
The use of CBBs remained similar in
2001 compared with 1993, with only a
slight increase in utilization. Like
-blockers, however, CCB use signiﬁ-
cantly decreased from 1993 to 1998 be-
forerapidlyincreasingfrom1998to2001
(Fig. 1). Similar patterns of utilization
were observed among the groups, with
the exception of those aged 65 years,
whichshowedboththehighestutilization
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(Table 2). The largest increase in utiliza-
tion occurred with statin therapy, with a
223% relative increase in utilization be-
tween 1993 and 2001 (Fig. 1). Overall,
the APC increase in statin use was 17.9%
withatwofoldincreaseinutilizationrates
between 1997 and 2001 compared with
1993 and 1997 (Table 2). Similar in-
creases in utilization rates were observed
regardless of age or sex, with men and
those aged 65 years more likely to re-
ceivestatintherapyoverthestudyperiod.
All-cause hospitalization
Hospitalization rates decreased by 16%,
from 300.3 per 1,000 in 1993 to 252.7
per 1,000 in 2001 (P  0.05). Similar
declines were observed in men, women,
and in those aged 65 years. Although a
decline was also observed in those aged
65 years, the rate of decline was not as
large compared with the other groups ex-
amined and was not statistically signiﬁ-
cant (Table 2). The largest reduction in
hospitalization rates occurred for cere-
brovascular-related hospitalizations, with
a signiﬁcant 5.4% APC decrease between
1993 and 2001 (Table 2). Importantly,
the largest reductions were observed in
those aged 65 years (APC decrease of
6.4%), with similar reductions being ob-
servedinbothmenandwomen(Table2).
Rates of cardiac-related hospitalizations
alsodeclinedsigniﬁcantlyby2%annually
during this period. Few differences ex-
isted between sex or age-groups, how-
ever. Men had higher rates of cardiac-
related admission than women (sRR 1.2,
P  0.05), as did those aged 65 years
compared with aged 65 years (sRR 4.0,
P  0.05).
All-cause mortality
Despite increased utilization of evidence-
based drug therapies and observed de-
clines in hospital-related morbidity from
1993 to 2001, mortality rates remained
remarkably stable during this period (Ta-
ble2),irrespectiveofsexorage.Although
slightly larger rates of decline were ob-
served in people with diabetes aged 65
years,therewasnostatisticaldifferencein
theratesobservedin1993comparedwith
those in 2001 for this group (P  0.05).
CONCLUSIONS — The adjusted
prevalence of diabetes in Saskatchewan,
Canada increased by 34% from 1993 to
2001, with a consistent annual percent-
age increase of 4.3%. Although these re-
sults are similar to other studies, the
overall rate of increase appears lower. For
example,inalargestudy(2)conductedin
Ontario, Canada, from 1995 to 2000, the
adjusted prevalence of diabetes increased
from 5.2 to 6.9%, representing a 33% rel-
ativeincrease.Duringthatsametime(i.e.,
1995and2000),ourobservedincreaseof
25% (5.2–6.5%, respectively) in preva-
lence is 24% lower than that observed in
Ontario. Furthermore, the Ontario study
included all people aged 20 years,
whereas our study was restricted to only
those aged 30 years and thus likely at
higher overall risk for diabetes; the differ-
ence in observed rates would likely be
larger if the previous study were to be re-
stricted to only those people aged 30
years. Regardless, our data highlight the
Figure 1—Overall direct age- and sex-standardized prescription rates between 1993 and 2001.
Trends in cardiovascular risk management
2140 DIABETES CARE, VOLUME 31, NUMBER 11, NOVEMBER 2008disturbing trend of increasing diabetes
ratesandisconsistentwithstudiesinboth
Canada and the U.S. (2,18). Importantly,
however, our data also suggest that in
people aged 65 years, the rate of in-
crease in diabetes prevalence signiﬁcantly
slowed between 1998 and 2001. The rea-
son for this change and whether this is a
trend continued in more recent years is
unknown.
An increase in prescription claims for
select evidence-based drug therapies sug-
gests that both providers and patients are
moving toward more aggressive manage-
ment of cardiovascular risk factors in di-
abetes. Signiﬁcant increases in the
utilization of antihypertensive therapies
from1993to2001resultedinalmosthalf
of all people with diabetes using an anti-
hypertensiveagentin2001.Incontrastto
previous studies (6,19,20), we found
higherutilizationratesamongwomen,al-
though the gap between sexes signiﬁ-
cantly narrowed during our study period.
Similar to previous studies (6), the largest
increase occurred with ACE inhibitor
therapy, with one-third of all diabetic pa-
tients receiving ACE inhibitors. Men,
however,weremorelikelytoreceiveACE
inhibitor therapy than women, and it has
been speculated that this differential pre-
scribing may result from either an in-
creasedrecognitionofatheroscleroticrisk
in men or concerns for adverse effects in
women (e.g., teratogenic risk) (6). Inter-
estingly, although decreases in both
-blocker and CCB therapy during the
overall period were observed, utilization
withinbothclassessigniﬁcantlyincreased
inthelater1990s.Thiscoincideswiththe
publication of several antihypertensive
trials that may have inﬂuenced physician
prescribing and overall utilization (5).
Similarly, statin use signiﬁcantly in-
creased after 1997, corresponding to the
publication of several landmark clinical
trials of statins (5).
Several studies (11,21–23) have
failed to demonstrate a consistent trend
with respect to cardiovascular-related
events in patients with diabetes. Our re-
sults suggest that signiﬁcant improve-
ments in the morbidity of diabetes
occurred, demonstrated by signiﬁcant re-
ductionsinboththeratesofall-causehos-
pitalization and cardiovascular-related
events. Overall, rates of cerebrovascular-
and cardiac-related hospitalizations de-
clined by 36 and 19%, respectively, dur-
ing this period. Moreover, unlike
previousstudies(11,21)thatobservedre-
ductions in men only, we observed simi-
lar reductions in cardiovascular-related
events among both sexes. Although the
reason for these trends is unknown, one
would assume that improvements in pa-
tientawarenessofdiabetescomplications,
improvements in overall patient manage-
ment, and more aggressive evidence-
based drug therapies aimed at
cardiovascular risk reduction likely
played a role (19,20,24).
Despite substantial improvements in
the utilization of evidence-based drug
therapies and reductions in morbidity in
patientswithdiabetes,wedidnotobserve
reductions in mortality during the study
period.Thisisincontrasttoseveralrecent
reports (2,10–14). Lipscombe et al. (2)
reported a 25% decrease in the adjusted
mortality rate in people with diabetes be-
tween 1995 and 2005 in Ontario, Can-
ada. Other studies, however, have
reported no signiﬁcant change in overall
mortality (11) or even increased cardio-
vascular-related mortality rates in people
with diabetes (22,23). Studies have also
suggested, however, that sex-related dif-
ferences in mortality may exist, with sev-
eralstudies(11,14,21)observingchanges
favoring men.
The reason for the discrepancies in
mortality between studies is not known,
but several possible explanations exist.
First,despiteourlargepopulation,impre-
cision in the adjusted mortality rates may
haveprecludedidentiﬁcationofsmallbut
clinically important reductions in mortal-
ity, particularly in the 65 years age-
group. Second, rates of undiagnosed
diabetes may have affected our results if
these rates were substantially higher in
1993 than 2000. If so, mortality events
misclassiﬁed to those with undiagnosed
diabetes may have artiﬁcially lowered the
diabetes mortality rates in 1993 and ne-
gate any observed mortality beneﬁt. Al-
though data on undiagnosed diabetes is
not available in the administrative data,
estimatesfromtheU.S.suggestthatundi-
agnosed diabetes rates have remained
constant throughout our period of study
(25).Finally,itispossibleourtimeperiod
was insufﬁcient to observe the longer-
termbeneﬁtsonmortalityassociatedwith
improved prescribing of evidence-based
therapies.Moreover,ouroutcomewasre-
stricted to all-cause mortality, and it is
therefore possible that reductions in
cause-speciﬁc mortality may have oc-
curred during the time period that we
were unable to capture. However, as pre-
viously shown, the majority of mortality
in patients with diabetes is cardiovascular
related (11,21).
Our study has several strengths, in-
cluding the use of large, comprehensive,
administrative health data of an un-
selected population of patients with dia-
betes for our estimates; inclusion of all
adult age-groups; and the long duration
of follow-up. There are some limitations,
however. First, although a previously val-
idated algorithm was used to identify di-
abetes (16), it is possible that some cases
may have been missed due to the admin-
istrative nature of the data. Second, we
were unable to evaluate the impact of
changes in diagnostic criteria for diabetes
that have occurred during our period of
study. It is possible that the observed in-
crease in diabetes prevalence may be par-
tially related to more stringent diagnostic
criteria for glucoses tolerance; on the
other hand, the rate of increase in preva-
lencewasmoreorlessconstant.Third,we
are unable to make any assertions about
the appropriateness of the health services
delivered (pharmacological or hospital-
izations).Fourth,wedidnothavedataon
clinical parameters and, perhaps more
importantly, patient self-care behaviors.
It is possible that medication nonadher-
enceorweightgain,forexample,mayne-
gate beneﬁts of increased dispensation of
evidence-based therapies. If this was the
case, however, we would also expect to
see increased rates of hospitalizations for
important clinical events, which we did
not observe.
The results of this study have im-
portant public health implications for
the management of diabetes both near
andlongterm.Whilemanystudieshave
criticized the prescribing rates of evi-
dence-based drug therapies in patients
withdiabetes,bothpatientsandprovid-
ers should be commended for the sig-
niﬁcant improvements that have
alreadyoccurred.Diabetesisamultifac-
eted, complex disease, and although
more work is required, current trends
suggest that treatment gaps in patients
with diabetes are indeed narrowing. Al-
though one cannot say for certain, it
wouldappearthatthemountingclinical
evidence and guideline endorsements
have resulted in signiﬁcant positive
changesinprescribingatthepopulation
level, with more intensive utilization of
pharmacological therapies. While we
did not observe reductions in mortality,
signiﬁcant improvement in the use of
evidence-based drug therapies and
declines in major cardiovascular co-
Eurich and Associates
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creasing dark cloud of diabetes, there
may indeed be a silver lining.
Acknowledgments— D.T.E. is supported by
a Population Health Investigator Award from
the Alberta Heritage Foundation for Medical
Research (AHFMR). J.-M.G. is supported by a
full-time Health Research Studentship
through the AHFMR and a Canada Graduate
Scholarship from the Canadian Institutes of
HealthResearch(CIHR).S.H.S.isanewinves-
tigator supported by the CIHR. J.A.J. holds a
Canada Research Chair in Diabetes Health
Outcomes, is a Health Scholar through the
AHFMR, and is the Chair of a New Emerging
Team (NET) Grant to the Alliance for Cana-
dian Health Outcomes Research in Diabetes
(ACHORD). The ACHORD NET Grant is
sponsored by the Canadian Diabetes Associa-
tion, the Heart and Stroke Foundation of Can-
ada, the Kidney Foundation of Canada, and
CIHR (the Institute of Nutrition, Metabolism,
and Diabetes and the Institute of Circulatory
and Respiratory Health).
This study is based on nonidentiﬁable data
provided by the Saskatchewan Ministry of
Health. The interpretation and conclusions
contained herein do not necessarily represent
those of the government of Saskatchewan or
the Saskatchewan Ministry of Health. These
sponsors did not play any role in study design
or conduct; collection, analysis, and interpre-
tation of data; writing of the report; or in the
decision to submit the report for publication.
All authors declare that they have no relation-
ship or ﬁnancial conﬂicts of interest. D.T.E.
had full access to all the data in the study and
takesresponsibilityfortheintegrityofthedata
and the accuracy of the data analysis.
All authors took part in the planning and
design of the study. D.T.E. and J.A.J. obtained
the data. D.T.E. conducted the statistical anal-
yses. All authors had access to the data and
participated in the interpretation of the data.
D.T.E. and J.-M.G. wrote the ﬁrst draft of the
report. All authors reviewed and revised the
paper for important intellectual content and
gave approval for the version to be published.
References
1. Wild S, Roglic G, Green A, Sicree R, King
H: Global prevalence of diabetes: esti-
mates for the year 2000 and projections
for 2030. Diabetes Care 27:1047–1053,
2004
2. LipscombeLL,HuxJE:Trendsindiabetes
prevalence, incidence, and mortality in
Ontario, Canada 1995–2005: a popula-
tion-based study. Lancet 369:750–756,
2007
3. Morrish NJ, Wang SL, Stevens LK, Fuller
JH, Keen H: Mortality and causes of death
in the WHO Multinational Study of Vas-
cular Disease in Diabetes. Diabetologia 44
(Suppl. 2):S14–S21, 2001
4. World Health Organization: Global strat-
egy on diet, physcial activity and health:
diabetes [article online], 2008. Available
from http://www.who.int/dietphysical
activity/publications/facts/diabetes/en/
print.html. Accessed 8 April 2008
5. HuangES,MeigsJB,SingerDE:Theeffect
of interventions to prevent cardiovascular
disease in patients with type 2 diabetes
mellitus. Am J Med 111:633–642, 2001
6. McAlister FA, Campbell NRC, Duong-
Hua M, Chen Z, Tu K: Antihypertensive
medication prescribing in 27,822 el-
derly Canadians with diabetes over the
past decade. Diabetes Care 29:836-841,
2006
7. CohenFJ,NeslusanCA,ConklinJE,Song
X: Recent antihyperglycemic prescribing
trends for U.S. privately insured patients
with type 2 diabetes. Diabetes Care 26:
1847–1851, 2003
8. Lusignan S, Sismanidis C, Carey IM,
DeWildeS,RichardsN,CookDG:Trends
in the prevalence and management of di-
agnosed type 2 diabetes 1994–2001 in
England and Wales. BMC Fam Pract 6:13,
2005
9. Teeling M, Bennett K, Feely J: The inﬂu-
enceofguidelinesontheuseofstatins:anal-
ysis of prescribing trends 1998–2002. Br J
Clin Pharmacol 59:227–232, 2005
10. Thomas RJ, Palumbo PJ, Melton LJ III,
Roger VL, Ransom J, O’Brien PC, Leibson
CL: Trends in the mortality burden asso-
ciated with diabetes mellitus: a popula-
tion-based study in Rochester, Minn,
1970–1994. Arch Intern Med 163:445–
451, 2003
11. GreggEW,GuQ,ChengYJ,NarayanKM,
Cowie CC: Mortality trends in men and
women with diabetes, 1971 to 2000. Ann
Intern Med 147:149–155, 2007
12. Tierney EF, Cadwell BL, Engelgau MM,
ShireleyL,ParsonsSL,MoumK,GeissLS:
Declining mortality rate among people
with diabetes in North Dakota, 1997–
2002.DiabetesCare27:2723–2725,2004
13. FoxCS,CoadyS,SorliePD,LevyD,Meigs
JB, D’Agostino RB Sr, Wilson PW, Savage
PJ: Trends in cardiovascular complica-
tions of diabetes. JAMA 292:2495–2499,
2004
14. Stovring H, Andersen M, Beck-Nielsen H,
Green A, Vach W: Rising prevalence of
diabetes: evidence from a Danish phar-
maco-epidemiological database. Lancet
362:537–538, 2003
15. Eurich DT, Majumdar SR, McAlister FA,
Tsuyuki RT, Johnson JA: Improved clini-
cal outcomes associated with metformin
inpatientswithdiabetesandheartfailure.
Diabetes Care 28:2345–2351, 2005
16. Hux JE, Ivis F, Flintoft V, Bica A: Diabetes
in Ontario: determination of prevalence
and incidence using a validated adminis-
trative data algorithm. Diabetes Care 25:
512–516, 2002
17. Wang J, Williams DE, Narayan KM, Geiss
LS: Declining death rates from hypergly-
cemic crisis among adults with diabetes,
U.S.,1985–2002.DiabetesCare29:2018–
2022, 2006
18. Kanjilal S, Gregg EW, Cheng YJ, Zhang
P, Nelson DE, Mensah G, Beckles GL:
Socioeconomic status and trends in dis-
parities in 4 major risk factors for car-
diovascular disease among US adults,
1971–2002. Arch Intern Med 166:2348-
2355, 2006
19. Hajjar I, Kotchen TA: Trends in preva-
lence, awareness, treatment, and control
of hypertension in the United States,
1988–2000. JAMA 290:199–206, 2003
20. Imperatore G, Cadwell BL, Geiss L, Saad-
inne JB, Williams DE, Ford ES, Thomp-
son TJ, Narayan KM, Gregg EW: Thirty-
year trends in cardiovascular risk factor
levelsamongUSadultswithdiabetes:Na-
tional Health and Nutrition Examination
Surveys, 1971–2000. Am J Epidemiol 160:
531–539, 2004
21. Gu K, Cowie CC, Harris MI: Diabetes and
decline in heart disease mortality in US
adults. JAMA 281:1291–1297, 1999
22. Pavkov ME, Sievers ML, Knowler WC,
Bennett PH, Nelson RG: An explanation
for the increase in heart disease mortality
rates in diabetic Pima Indians: effect of
renal replacement therapy. Diabetes Care
27:1132–1136, 2004
23. Hoehner CM, Williams DE, Sievers ML,
Knowler WC, Bennett PH, Nelson RG:
Trends in heart disease death rates in di-
abeticandnondiabeticPimaIndians.JDi-
abetes Complications 20:8–13, 2006
24. Saaddine JB, Cadwell B, Gregg EW, En-
gelgau MM, Vinicor F, Imperatore G,
Narayan KM: Improvements in diabetes
processes of care and intermediate out-
comes: United States, 1988–2002. Ann
Intern Med 144:465–474, 2006
25. Centers for Disease Control and Preven-
tion: Prevalence of diabetes and impaired
fasting glucose: United States, 1999–
2000. MMWR. Morbidity and Mortality
Weekly Report 52:833–837, 2003
Trends in cardiovascular risk management
2142 DIABETES CARE, VOLUME 31, NUMBER 11, NOVEMBER 2008